Vigil Neuroscience, Inc. (VIGL) Stock Analysis & Investment Frameworks
Vigil Neuroscience, Inc. (VIGL) stock analysis on Invetso. Review Vigil Neuroscience, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Vigil Neuroscience, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Vigil Neuroscience, Inc. Key Financial Metrics
- Market Cap: $375.71M
- Revenue: $N/A
- ROE: -89.69%
- ROIC: -106.03%
- Dividend Yield: N/A
About Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc., founded in 2020 and headquartered in Cambridge, Massachusetts, is a biotechnology company concentrating on microglia to develop transformative treatments for neurodegenerative diseases. The firm aims to provide disease-altering therapies for patients, their families, and caregivers affected by both rare and widespread neurological disorders. The company's primary experimental therapy is VGL101, a fully human monoclonal antibody (mAb). This compound is engineered to activate the triggering receptor expressed on myeloid cells 2 (TREM2) and is currently in Phase I clinical trials. VGL101 is being investigated for its potential in treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), cerebral adrenoleukodystrophy, and Alzheimer's disease. Furthermore, Vigil Neuroscience is also advancing an orally administered small molecule designed to act as a TREM2 agonist. This alternative therapeutic approach targets common neurodegenerative conditions associated with impaired microglial function.